Citation Correction
In the original publication [1], Section “3. Discussion”. Original sentence: “In ovarian cancer models, co-treatment with BMX-001 and PTX significantly reduced the cell viability of CAOV2 cells compared to PTX alone and downregulated the expression of BCL2, NF-κB, and IL-1β [49].”
Original citation for [49] is “Batinic-Haberle, I.; Tovmasyan, A.; Veade, A.; Spasojevic, I.; Reihani, S.; Secord, A. Mn porphyrin/ascorbate sensitizes serous epithelial ovarian cancer to chemotherapy. Free. Radic. Biol. Med. 2018, 128, S74–S75.” It has been correctly replaced with [2].
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
References
- Pan, T.; Alimi, O.A.; Liu, B.; Krishnan, M.A.; Kuss, M.; Shi, W.; Krishnamurthy, J.; Dong, J.J.; Oberley-Deegan, R.E.; Duan, B. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals 2025, 18, 1159. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Spasojevic, I.; da Silva, W.T.A.; Huang, Z.; Duan, W.; Du, L.; Chen, C.; Cao, J.; Zhang, S.; Lee, H.; Lo, G.; et al. Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth. Free Radic. Biol. Med. 2024, 224, S54–S55. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.